Nephrotoxicity by imatinib [3];Nefrotoxicidad por imatinib

Nefrologia

Volumn 23, Issue 3, 2003, Pages 273-274

  Diaz Rodriguez C ^a,b   Vasco, B ^a  

^a F P Hospital Virxe da Xunqueira   (Spain)

^b Servicio de Nefrologia   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; BCR ABL PROTEIN; IMATINIB; ANTINEOPLASTIC AGENT; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

AGED; CASE REPORT; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; KIDNEY TUBULE NECROSIS; LABORATORY TEST; LETTER; LIVER TOXICITY; NEPHROTOXICITY; CHEMICALLY INDUCED DISORDER; KIDNEY DISEASE; MALE;

AGED; ANTINEOPLASTIC AGENTS; HUMANS; KIDNEY DISEASES; MALE; PIPERAZINES; PYRIMIDINES;

EID: 0141450297     PISSN: 02116995     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (4)

1. Anne S. Tsao, Hagop Kantarjlan, Moshe Talpaz: STI-571 in chronic myelogenous leukaemia. British Journal of Haematology 119; 15-24, 2002.
2. Martín D, Marktel S, Bua, M. Armstrong L, Goldman JM, Apperley JF, Olavarría E: The use of imatinib (STI571) in chronic myeloid leukemia: some practical considerations. Haematologica 87: 979-988, 2002.
3. Martin H Cohen, Grant Williams, Johnson JR, Duan J, Gobburu J, Rahman A, Benson K, Leighton J, Kim SK, Wood R, Rothmann M, Chen G, Maung UK, Staten AM, Pazdur R. Capsules in the treatment of chronic myelogenous leukemia. Clinical Cancer Research 8: 925-942, 2002.
4. Kitiyakara C, Atichartakarn V: Renal failure associated with a specific inhibitor of BCR-ABL tyrosine kinase, STI 571. Nephrol Dial Transplant 17: 685-687, 2002.